PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2024/28 - Merz / Acorda*Civitas
Acquired
Acorda Therapeutics, Inc.
Description
Acorda is the parent company of a group of companies focused on therapies that restore function and improve the lives of people with MS, Parkinson's disease and other neurological diseases.
Acquired
Civitas Therapeutics, Inc.
Description
It is a wholly owned subsidiary, acquired in 2014, due to its Inbrija product development program and its ARCUS technology platform (the "ARCUS Platform"). The ARCUS Platform allows the administration of medicines, at this stage only Inbrija, through inhalation, transforming the molecules into a light and porous dry powder.
Acquiring
Merz Pharma GmbH & Co. KGaA
Description
Company focused on healthcare specialties, covering a spectrum of therapies for neurology, hepatology and dermatology, portfolio of injectables, devices and skin care products. In Portugal, it sells the medicines Xeomin and Axura, used as a muscle relaxant and in the treatment of moderate to severe Alzheimer's disease.
Sector
  • Health & Pharmaceutical
Activity (NACE)
Applicable legislation
Art. 37(1)(a) (Law 19)
Notification thresholds
Market Share threshold
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description

The merger operation consists of the acquisition, by Merz Pharma GmbH & Co. KgaA (“Merz”), of all global rights, assets and liabilities related to the Fampyra and Ibrija products and the ARCUS technology platform from Acorda Therapeutics Inc. and of Civitas Therapeutics, Inc., as well as the entire issued share capital of the Selling Parent Company in Acorda Ireland (together “Acquired Business”).
Timeline
2024-06-05
The AdC issued a non-opposition decision to the merger 28/2024 - Merz / Acorda*Civitas.
2024-05-17
Merz Pharma notifies the acquisition of sole control over Acorda and Civitas.
Click here to see your activities